[HTML][HTML] C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 …
EA Perez, RB Jenkins, AC Dueck… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
EA Perez, RB Jenkins, AC Dueck, AE Wiktor, PP Bedroske, SK Anderson, RP Ketterling…
Journal of clinical oncology, 2011•ncbi.nlm.nih.govPurpose Findings from the human epidermal growth factor receptor 2 (HER2)–positive
National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that
MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit
from adjuvant trastuzumab in patients with early-stage breast cancer. To further explore this
relationship, we investigated associations between MYC amplification and disease-free
survival (DFS) in a similar adjuvant trastuzumab HER2-positive breast cancer trial—North …
National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that
MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit
from adjuvant trastuzumab in patients with early-stage breast cancer. To further explore this
relationship, we investigated associations between MYC amplification and disease-free
survival (DFS) in a similar adjuvant trastuzumab HER2-positive breast cancer trial—North …
Abstract
Purpose
Findings from the human epidermal growth factor receptor 2 (HER2)–positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer. To further explore this relationship, we investigated associations between MYC amplification and disease-free survival (DFS) in a similar adjuvant trastuzumab HER2-positive breast cancer trial—North Central Cancer Treatment Group (NCCTG) N9831.
ncbi.nlm.nih.gov